Prices delayed by at least 15 minutes | Print
Immupharma PLC (IMM)
ORD 1POpen
2.50p
Previous close
2.60p
Trade high
2.80p
Volume
1,416,060
Year high
7.40p
Year low
0.85p
Dividend yield
–
Market capitalisation
£10.10 mn
P/E ratio
–
ISIN
GB0033711010
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 25/04/2025 | 04:28:05 | 2.36 | 86,000 | 2,029.60 |
| 25/04/2025 | 03:41:41 | 2.3651 | 115,000 | 2,719.87 |
| 25/04/2025 | 02:46:41 | 2.36 | 8,121 | 191.66 |
| 25/04/2025 | 02:43:50 | 2.4 | 100,000 | 2,400.00 |
| 25/04/2025 | 02:36:44 | 2.5198 | 7,779 | 196.02 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.